tradingkey.logo

Champions Oncology Q4 revenue beats analyst expectations

ReutersJul 23, 2025 8:16 PM


Overview

  • Champions Oncology fiscal Q4 revenue beats analyst expectations, per LSEG data

  • Adjusted EBITDA for fiscal Q4 beats consensus, reflecting operational efficiency

  • Fiscal 2025 revenue grows 14% yr/yr, driven by new data business


Outlook

  • Champions Oncology expects continued revenue growth in fiscal 2026

  • Company confident in further monetization of data offering

  • Champions sees strong pipeline heading into fiscal 2026


Result Drivers

  • DATA BUSINESS - New high-margin data business contributed $4.7 mln to annual revenue, driving overall growth

  • OPERATIONAL EFFICIENCY - Disciplined execution and operational improvements led to record adjusted EBITDA and reduced costs

  • MARKETING EXPENSES - Increased sales and marketing expenses due to expansion of data business development team and more conferences


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$12.30 mln

$12 mln (1 Analyst)

Q4 EPS

-$0.13

Q4 Adjusted EBITDA

Beat

-$1.02 mln

-$2.48 mln (1 Analyst)

Q4 Gross Margin

41.0%

Q4 Income from Operations

Beat

-$2 mln

-$3.23 mln (1 Analyst)


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 34.6% above its July 22 closing price of $7.85

  • The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 38 three months ago

Press Release: ID:nACSCgv63a

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI